Artikel
More information about Artikel
DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3
Real-World Evidence and Phase IV studies in CRSwNP
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.
Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities
Beyfortus is an RSV immunization designed for all infants, for protection against RSV disease of the lower respiratory tract (LRTD)
Reflekter over ny tilgang til KOL
At få en forståelse for type 2 inflammation* kan belyse hvorfor nogle KOL-patienter fortsætter med at få eksacerbationer.1
FLUNITY-HD : the largest individually randomised influenza vaccine effectiveness study of its kind.
FLUNITY-HD is the largest individually randomised influenza vaccine effectiveness study, with nearly half a million older adults across multiple seasons.1